UA113733C2 - Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу - Google Patents
Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу Download PDFInfo
- Publication number
- UA113733C2 UA113733C2 UAA201313464A UAA201313464A UA113733C2 UA 113733 C2 UA113733 C2 UA 113733C2 UA A201313464 A UAA201313464 A UA A201313464A UA A201313464 A UAA201313464 A UA A201313464A UA 113733 C2 UA113733 C2 UA 113733C2
- Authority
- UA
- Ukraine
- Prior art keywords
- still
- type
- соон
- compound
- structural units
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 150000001875 compounds Chemical class 0.000 title claims abstract description 65
- 230000002265 prevention Effects 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 23
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 19
- 229920001577 copolymer Polymers 0.000 claims description 18
- 230000006378 damage Effects 0.000 claims description 17
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 claims description 14
- 210000002151 serous membrane Anatomy 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 229920002873 Polyethylenimine Polymers 0.000 claims description 5
- 238000002357 laparoscopic surgery Methods 0.000 claims description 4
- 229920002717 polyvinylpyridine Polymers 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 101100367084 Caenorhabditis elegans such-1 gene Proteins 0.000 claims 4
- 244000005894 Albizia lebbeck Species 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 2
- 101500020117 Aedes aegypti Sialokinin Proteins 0.000 claims 1
- 102100035472 DNA polymerase iota Human genes 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 101001094672 Homo sapiens DNA polymerase iota Proteins 0.000 claims 1
- 101150065603 PLEK gene Proteins 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 15
- 230000002980 postoperative effect Effects 0.000 abstract description 8
- 230000000181 anti-adherent effect Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 34
- 230000008569 process Effects 0.000 description 33
- 239000000243 solution Substances 0.000 description 27
- 210000000683 abdominal cavity Anatomy 0.000 description 26
- 229920000642 polymer Polymers 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 14
- 239000000499 gel Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 8
- 210000004303 peritoneum Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000003815 abdominal wall Anatomy 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- -1 polytetrafluoroethylene Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 229940119743 dextran 70 Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 210000000504 visceral peritoneum Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010060932 Postoperative adhesion Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011119848/15A RU2011119848A (ru) | 2011-05-17 | 2011-05-17 | Способ профилактики спайкообразования |
| PCT/IB2012/052483 WO2012156938A1 (ru) | 2011-05-17 | 2012-05-17 | Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA113733C2 true UA113733C2 (xx) | 2017-03-10 |
Family
ID=49254499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201313464A UA113733C2 (xx) | 2011-05-17 | 2012-05-17 | Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу |
Country Status (4)
| Country | Link |
|---|---|
| CU (1) | CU20130154A7 (xx) |
| MY (1) | MY198042A (xx) |
| RU (1) | RU2011119848A (xx) |
| UA (1) | UA113733C2 (xx) |
-
2011
- 2011-05-17 RU RU2011119848/15A patent/RU2011119848A/ru unknown
-
2012
- 2012-05-17 MY MYPI2014000195A patent/MY198042A/en unknown
- 2012-05-17 UA UAA201313464A patent/UA113733C2/uk unknown
-
2013
- 2013-11-18 CU CU2013000154A patent/CU20130154A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20130154A7 (es) | 2014-05-27 |
| RU2011119848A (ru) | 2012-11-27 |
| MY198042A (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3228331B1 (en) | Biocompatible hemostatic product and preparation method thereof | |
| ES2427565T3 (es) | Péptidos autoensambladores para promover la hemostasia | |
| EP2012842B1 (en) | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions | |
| JP2020114442A (ja) | 癒着防止のためのハイドロゲル膜 | |
| Brochhausen et al. | Intraperitoneal adhesions—an ongoing challenge between biomedical engineering and the life sciences | |
| EP3777875A1 (en) | Surgical methods employing purified amphiphilic peptide compositions | |
| US6037331A (en) | Compositions for prevention of inflammation and adhesion formation uses thereof | |
| BRPI0721211A2 (pt) | uso de um tensoativo e um selante mÉdico, mÉtodo para tratar as condiÇÕes de ouvido, nariz e garganta, e, composiÇço | |
| AU2017221883B2 (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| UA113733C2 (xx) | Сполуки для лікування або профілактики спайкоутворення, фармацевтичні композиції на їх основі та спосіб профілактики і лікування спайкового процесу | |
| RU2624228C1 (ru) | Соединения для лечения или профилактики спайкообразования, фармацевтические композиции на их основе и способ профилактики и лечения спаечного процесса | |
| ES2746250T3 (es) | Compuestos para la profilaxis y tratamiento del proceso de adherencia | |
| Zeng et al. | Assessment of postoperative adhesion formation in a rat cecum model using different techniques. | |
| NZ618882B2 (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| RU2262942C2 (ru) | Способ обтурации наружных трубчатых свищей пищеварительного тракта и остаточных полостей абдоминальной области | |
| RU2233655C1 (ru) | Средство для местного применения и способ лечения и профилактики опухолевого поражения печени и брюшины с его использованием | |
| RU2197246C2 (ru) | Глазной препарат и способ его получения | |
| OA16780A (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process. | |
| Nueffer et al. | Share this story: RELATED ARTICLES | |
| AU2014203694A1 (en) | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions |